Experimental Drug Yields Dramatic Weight Loss
Eli Lilly reported that participants receiving the experimental drug retatrutide lost an average of 28 percent of their body weight after 80 weeks. The results were presented in a study published by the New York Times on May 21, 2026. The findings suggest the drug could become a significant option for obesity treatment pending further regulatory review.
- ▪The drug retatrutide was administered via injection to study participants.
- ▪Participants lost 28% of their body weight on average after 80 weeks of treatment.
- ▪The study was reported by journalists Gina Kolata and Rebecca Robbins.
- ▪Eli Lilly’s headquarters are located in Indianapolis.
Opening excerpt (first ~120 words) tap to expand
AdvertisementSKIP ADVERTISEMENTYou have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.Supported bySKIP ADVERTISEMENTExperimental Drug Yields Dramatic Weight LossPeople who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.Listen · 7:01 min Share full article569Eli Lilly’s headquarters in Indianapolis.Credit...AJ Mast/BloombergBy Gina Kolata and Rebecca RobbinsPublished May 21, 2026Updated May 22, 2026Leer en español !function(){var e="gps_module_impressions",s="gps_suppress_module",t=new URLSearchParams(window.location.search),o="1"===t.get("gps_debug")?function(e,s){console.log("[gps]",e,void…
Excerpt limited to ~120 words for fair-use compliance. The full article is at NYT > Top Stories.
Discussion
0 commentsMore from NYT > Top Stories
